ASH 2022 | ASH 2022 LBA: Findings from the ALIFE2 trial
Saskia Middeldorp, MD, PhD, Radboud University Medical Center, Nijmegen, Netherlands, discusses the late-breaking abstract she presented at the 2022 ASH Annual Meeting on the ALIFE2 trial (NTR3361). This study assessed the efficacy of low-molecular-weight heparin versus standard care for women with recurrent miscarriage and inherited thrombophilia. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bayer: Honoraria; Pfizer: Honoraria, Research Funding; Boehringer Ingelheim: Honoraria, Research Funding; Abbvie: Honoraria; Viatris: Honoraria; Sanofi: Honoraria; Norgine: Honoraria; GSK: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; Astra Zeneca: Honoraria.
